NDAQ Nasdaq Inc.

Annual Changes to the Nasdaq Biotechnology Index

Annual Changes to the Nasdaq Biotechnology Index

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 100 securities will be added to the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqABUSArbutus Biopharma Corporation
NasdaqADAPAdaptimmune Therapeutics plc
NasdaqAKUSAkouos, Inc.
NasdaqALTAltimmune, Inc.
NasdaqALVRAlloVir, Inc.
NasdaqALXOALX Oncology Holdings Inc.
NasdaqAMTIApplied Molecular Transport Inc.
NasdaqANNXAnnexon, Inc.
NasdaqAPLTApplied Therapeutics, Inc.
NasdaqAPREAprea Therapeutics, Inc.
NasdaqARCTArcturus Therapeutics Holdings Inc.
NasdaqARQTArcutis Biotherapeutics, Inc.
NasdaqAVDLAvadel Pharmaceuticals plc
NasdaqAZNAstraZeneca PLC
NasdaqBDTXBlack Diamond Therapeutics, Inc.
NasdaqBEAMBeam Therapeutics Inc.
NasdaqBNTXBioNTech SE
NasdaqCABACabaletta Bio, Inc.
NasdaqCALACalithera Biosciences, Inc.
NasdaqCDXSCodexis, Inc.
NasdaqCLVSClovis Oncology, Inc.
NasdaqCNCEConcert Pharmaceuticals, Inc.
NasdaqCNSTConstellation Pharmaceuticals, Inc.
NasdaqCRNXCrinetics Pharmaceuticals, Inc.
NasdaqCRTXCortexyme, Inc.
NasdaqFMTXForma Therapeutics Holdings, Inc.
NasdaqFPRXFive Prime Therapeutics, Inc.
NasdaqFREQFrequency Therapeutics, Inc.
NasdaqFULCFulcrum Therapeutics, Inc.
NasdaqFUSNFusion Pharmaceuticals Inc.
NasdaqGBIOGeneration Bio Co.
NasdaqGMDAGamida Cell Ltd.
NasdaqHARPHarpoon Therapeutics, Inc.
NasdaqIDYAIDEAYA Biosciences, Inc.
NasdaqIGMSIGM Biosciences, Inc.
NasdaqIMABI-MAB
NasdaqIMUXImmunic, Inc.
NasdaqIMVTImmunovant, Inc.
NasdaqINZYInozyme Pharma, Inc.
NasdaqISEEIVERIC bio, Inc.
NasdaqITOSiTeos Therapeutics, Inc.
NasdaqJNCEJounce Therapeutics, Inc.
NasdaqKALAKala Pharmaceuticals, Inc.
NasdaqKALVKalVista Pharmaceuticals, Inc.
NasdaqKDMNKadmon Holdings, Inc.
NasdaqKDNYChinook Therapeutics, Inc.
NasdaqKLDOKaleido Biosciences, Inc.
NasdaqKMDAKamada Ltd.
NasdaqKNSAKiniksa Pharmaceuticals, Ltd.
NasdaqKROSKeros Therapeutics, Inc.
NasdaqKRYSKrystal Biotech, Inc.
NasdaqKZRKezar Life Sciences, Inc.
NasdaqLEGNLegend Biotech Corporation
NasdaqLRMRLarimar Therapeutics, Inc.
NasdaqMDGLMadrigal Pharmaceuticals, Inc.
NasdaqMNOVMediciNova, Inc.
NasdaqMRNSMarinus Pharmaceuticals, Inc.
NasdaqMRSNMersana Therapeutics, Inc.
NasdaqNKNantKwest, Inc.
NasdaqNKTXNkarta, Inc.
NasdaqNLTXNeoleukin Therapeutics, Inc.
NasdaqNRIXNurix Therapeutics, Inc.
NasdaqNVAXNovavax, Inc.
NasdaqNXTCNextCure, Inc.
NasdaqOCULOcular Therapeutix, Inc.
NasdaqODTOdonate Therapeutics, Inc.
NasdaqORICOric Pharmaceuticals, Inc.
NasdaqOVIDOvid Therapeutics Inc.
NasdaqPAHCPhibro Animal Health Corporation
NasdaqPANDPandion Therapeutics Inc.
NasdaqPASGPassage Bio, Inc.
NasdaqPCVXVaxcyte, Inc.
NasdaqPLRXPliant Therapeutics, Inc.
NasdaqPRTKParatek Pharmaceuticals, Inc.
NasdaqPRVBProvention Bio, Inc.
NasdaqPSTXPoseida Therapeutics, Inc.
NasdaqRAPTRAPT Therapeutics, Inc.
NasdaqRDHLRedhill Biopharma Ltd.
NasdaqREPLReplimune Group, Inc.
NasdaqRLAYRelay Therapeutics, Inc.
NasdaqRLMDRelmada Therapeutics, Inc.
NasdaqRNAAvidity Biosciences, Inc.
NasdaqRPRXRoyalty Pharma plc
NasdaqRPTXRepare Therapeutics Inc.
NasdaqRVMDRevolution Medicines, Inc.
NasdaqSELBSelecta Biosciences, Inc.
NasdaqSMMTSummit Therapeutics Inc.
NasdaqSNDXSyndax Pharmaceuticals, Inc.
NasdaqSPROSpero Therapeutics, Inc.
NasdaqSTROSutro Biopharma, Inc.
NasdaqSURFSurface Oncology, Inc.
NasdaqSWTXSpringWorks Therapeutics, Inc.
NasdaqTCRRTCR2 Therapeutics Inc.
NasdaqVIEViela Bio, Inc.
NasdaqVIRVir Biotechnology, Inc.
NasdaqVSTMVerastem, Inc.
NasdaqVYNEVYNE Therapeutics Inc.
NasdaqXENEXenon Pharmaceuticals Inc.
NasdaqZIOPZIOPHARM Oncology Inc
NasdaqZNTLZentalis Pharmaceuticals, Inc.

As a result of the reconstitution, the following 16 securities will be removed from the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqADMAADMA Biologics Inc
NasdaqAMRSAmyris, Inc.
NasdaqAXNXAxonics Modulation Technologies, Inc.
NasdaqCERSCerus Corporation
NasdaqCRBPCorbus Pharmaceuticals Holdings, Inc.
NasdaqEOLSEvolus, Inc.
NasdaqEYPTEyePoint Pharmaceuticals, Inc.
NasdaqGLYCGlycoMimetics, Inc.
NasdaqGRTSGritstone Oncology, Inc.
NasdaqLXRXLexicon Pharmaceuticals, Inc.
NasdaqNVCRNovoCure Limited
NasdaqOPTNOptiNose, Inc.
NasdaqPRQRProQR Therapeutics N.V.
NasdaqQTRXQuanterix Corporation
NasdaqSLDBSolid Biosciences Inc.
NasdaqTECHBio-Techne Corp

About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on , on Twitter , or at .

Media Relations Contact

Emily Pan

(646) 637-3964

Issuer & Investor Contact

Index Client Services

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG-



EN
12/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nasdaq Inc.

 PRESS RELEASE

Nasdaq to Hold Third Quarter 2025 Investor Conference Call

Nasdaq to Hold Third Quarter 2025 Investor Conference Call NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) has scheduled its third quarter 2025 financial results announcement.   Who:Nasdaq’s CEO, CFO, and additional members of its senior management team  What:Review Nasdaq’s third quarter 2025 financial results  When:Tuesday, October 21, 2025 Results Call: 8:00 AM ET   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations we...

 PRESS RELEASE

Nasdaq and AWS to Advance Capital Markets and Banking Infrastructure A...

Nasdaq and AWS to Advance Capital Markets and Banking Infrastructure Across the Financial System Strategic cloud deployment of Nasdaq Calypso on AWS will empower institutions to modernize end-to-end infrastructure, enhance resilience and unlock innovation at scale NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nasdaq and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company, today announced an expansion of their strategic technology partnership by giving financial institutions the option of deploying Nasdaq Calypso on AWS. It will be offered as a fully managed service powered by AW...

 PRESS RELEASE

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Sto...

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date September 15, 2025 NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of September 15, 2025, short interest in 3,341 Nasdaq Global MarketSM securities totaled 14,035,983,054 shares compared with 13,901,511,651 shares in 3,315 Global Market issues reported for the prior settlement date of August 29, 2025. The mid-September short interest represents 2.49 days compared with 2.39 days for the prior reporting period. Short interest in 1,673 securities on The Nasdaq Capit...

 PRESS RELEASE

Delisting of Securities from The Nasdaq Stock Market

Delisting of Securities from The Nasdaq Stock Market NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the warrants of Digital Brands Group, Inc. Digital Brands Group, Inc.’s warrants were suspended on December 18, 2024 and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals Inc.’s stock was suspended on June 20, 2025 and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the ...

 PRESS RELEASE

Nasdaq Halts Apollomics Inc., Ltd.

Nasdaq Halts Apollomics Inc., Ltd. NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional information requested from the company. The last sale price of the company’s ordinary shares was $18.4331 (Nasdaq: APLM), and warrants was $0.0191 (Nasdaq: APLMW). Trading will remain halted until Apollomics Inc. has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch